Mersana Inks Cancer Therapy Development Deal With Merck Germany - Mersana Therapeutics (NASDAQ:MRSN)

[ad_1]

  • Mersana Therapeutics Inc MRSN signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany’s Merck KGaA MKGAF MKKGY.
  • Mersana would receive $30 million in an upfront payment and up to $800 million in development, regulatory and commercial milestones.
  • RelatedMersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy.
  • Under the agreement, Mersana would develop cancer drug candidates against up to two targets that would utilize its platform to combine Merck KGaA’s proprietary antibodies.
  • Pre-clinical activities will be split between the companies. Merck Germany will be solely responsible for all clinical development and potential commercialization activities relating to any resulting product candidates.
  • Mersana said it was also eligible to receive royalties of up to low double-digit percentages on global net sales for any approved ADCs developed under the agreement.
  • Price Action: MRSN shares are down 2.68% at $5.82 on the last check Friday.
  • Photo Via Company

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.